These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 14508471)

  • 1. Cancer: the rules of attraction.
    Neckers L; Lee YS
    Nature; 2003 Sep; 425(6956):357-9. PubMed ID: 14508471
    [No Abstract]   [Full Text] [Related]  

  • 2. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors.
    Kamal A; Thao L; Sensintaffar J; Zhang L; Boehm MF; Fritz LC; Burrows FJ
    Nature; 2003 Sep; 425(6956):407-10. PubMed ID: 14508491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Heat shock protein 90: novel target for cancer therapy].
    Chen Y; Ding J
    Ai Zheng; 2004 Aug; 23(8):968-74. PubMed ID: 15301726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical trials referral resource. Current clinical trials of 17-AG and 17-DMAG.
    Ivy PS; Schoenfeldt M
    Oncology (Williston Park); 2004 May; 18(5):610, 615, 619-20. PubMed ID: 15209189
    [No Abstract]   [Full Text] [Related]  

  • 5. Mechanistic studies on Hsp90 inhibition by ansamycin derivatives.
    Onuoha SC; Mukund SR; Coulstock ET; Sengerovà B; Shaw J; McLaughlin SH; Jackson SE
    J Mol Biol; 2007 Sep; 372(2):287-97. PubMed ID: 17662999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting toxic proteins for turnover.
    La Spada AR; Weydt P
    Nat Med; 2005 Oct; 11(10):1052-3. PubMed ID: 16211038
    [No Abstract]   [Full Text] [Related]  

  • 7. Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents.
    Chiosis G; Caldas Lopes E; Solit D
    Curr Opin Investig Drugs; 2006 Jun; 7(6):534-41. PubMed ID: 16784024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heat shock protein inhibitor shows antitumor activity.
    Dunn FB
    J Natl Cancer Inst; 2002 Aug; 94(16):1194-5. PubMed ID: 12189221
    [No Abstract]   [Full Text] [Related]  

  • 9. Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone.
    Workman P
    Cancer Lett; 2004 Apr; 206(2):149-57. PubMed ID: 15013520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90.
    Ge J; Normant E; Porter JR; Ali JA; Dembski MS; Gao Y; Georges AT; Grenier L; Pak RH; Patterson J; Sydor JR; Tibbitts TT; Tong JK; Adams J; Palombella VJ
    J Med Chem; 2006 Jul; 49(15):4606-15. PubMed ID: 16854066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models.
    Banerji U; Walton M; Raynaud F; Grimshaw R; Kelland L; Valenti M; Judson I; Workman P
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):7023-32. PubMed ID: 16203796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic and diagnostic implications of Hsp90 activation.
    Kamal A; Boehm MF; Burrows FJ
    Trends Mol Med; 2004 Jun; 10(6):283-90. PubMed ID: 15177193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond.
    Georgakis GV; Younes A
    Future Oncol; 2005 Apr; 1(2):273-81. PubMed ID: 16555999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heat shock protein 90 inhibition by 17-allylamino-17- demethoxygeldanamycin: a novel therapeutic approach for treating hormone-refractory prostate cancer.
    Neckers L
    Clin Cancer Res; 2002 May; 8(5):962-6. PubMed ID: 12006507
    [No Abstract]   [Full Text] [Related]  

  • 15. Altered states: selectively drugging the Hsp90 cancer chaperone.
    Workman P
    Trends Mol Med; 2004 Feb; 10(2):47-51. PubMed ID: 15106614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamics.
    Workman P
    Mol Cancer Ther; 2003 Feb; 2(2):131-8. PubMed ID: 12589030
    [No Abstract]   [Full Text] [Related]  

  • 17. Dihydroquinone ansamycins: toward resolving the conflict between low in vitro affinity and high cellular potency of geldanamycin derivatives.
    Maroney AC; Marugan JJ; Mezzasalma TM; Barnakov AN; Garrabrant TA; Weaner LE; Jones WJ; Barnakova LA; Koblish HK; Todd MJ; Masucci JA; Deckman IC; Galemmo RA; Johnson DL
    Biochemistry; 2006 May; 45(17):5678-85. PubMed ID: 16634649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors.
    Beliakoff J; Bagatell R; Paine-Murrieta G; Taylor CW; Lykkesfeldt AE; Whitesell L
    Clin Cancer Res; 2003 Oct; 9(13):4961-71. PubMed ID: 14581371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of small molecule Hsp90 inhibitors: utilizing both forward and reverse chemical genomics for drug identification.
    Neckers L
    Curr Med Chem; 2003 May; 10(9):733-9. PubMed ID: 12678776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration.
    Waza M; Adachi H; Katsuno M; Minamiyama M; Sang C; Tanaka F; Inukai A; Doyu M; Sobue G
    Nat Med; 2005 Oct; 11(10):1088-95. PubMed ID: 16155577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.